Sectors

BSX
Boston Scientific Corporation
48.52
3 x 48.99
3 x 48.95
bid
ask
+
0.83
1.74%
11:04 AM
timesize
Ytd -49.11%
1y -52.63%
48.33
day range
49.47
47.68
52 week range
108.14
Open 48.56 Prev Close 47.69 Low 48.33 High 49.47 Mkt Cap 72.08B
Vol 7.44M Avg Vol 18.38M EPS 2.39 P/E 20.29 Forward P/E 12.77
Beta 0.62 Short Ratio 1.65 Inst. Own 94.92% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 07-29 50-d Avg 58.78 200-d Avg 84.39 1yr Est 79.37
Earning
Date For Estimate Reported Surprise surprise %
2026-04-22 2026-03 0.8 0.8 N/A N/A
2026-02-04 2025-12 0.78 0.8 0.02 2.56%
2025-10-22 2025-09 0.71 0.75 0.04 5.63%
2025-07-23 2025-06 0.72 0.75 0.03 4.17%
2025-04-23 2025-03 0.67 0.75 0.08 11.94%
2025-02-05 2024-12 0.65 0.7 0.05 7.69%
Upgrade / Downgrade
Date Firm Action From To
2026-06-01 Canaccord Genuity Upgrade Buy Buy
2026-05-29 Wolfe Research Downgrade Outperform Peer Perform
2026-05-28 Citigroup Upgrade Buy Buy
2026-05-28 Leerink Partners Upgrade Outperform Outperform
2026-05-28 Barclays Upgrade Overweight Overweight
2026-05-28 Wells Fargo Downgrade Overweight Equal-Weight
Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2025-02-18 BRENNAN DANIEL J Chief Financial Officer 225.81K Sale
2026-02-12 BROWN VANCE R General Counsel 54.24K Conversion of Exercise of derivative security
2026-04-30 BUTCHER ARTHUR C Officer 77.11K Conversion of Exercise of derivative security
2024-12-01 CARRUTHERS WENDY Officer 29.31K Sale
2026-02-12 FITZGERALD JOSEPH MICHAEL Officer 219.14K Conversion of Exercise of derivative security
2026-02-12 MAHONEY MICHAEL F Chief Executive Officer 1.79M Conversion of Exercise of derivative security
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 131.82M 6.29B 8.87%
2026-03-30 Vanguard Capital Management LLC 96.41M 4.60B 6.49%
2026-03-30 FMR, LLC 74.23M 3.54B 4.99%
2026-03-30 State Street Corporation 67.99M 3.24B 4.57%
2026-03-30 JPMORGAN CHASE & CO 33.35M 1.59B 2.24%
2026-03-30 Geode Capital Management, LLC 33.29M 1.59B 2.24%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 47.12M 2.25B 3.17%
2026-03-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 37.69M 1.80B 2.54%
2026-03-30 VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund 21.06M 1.00B 1.42%
2026-04-29 iShares Trust-iShares Core S&P 500 ETF 19.18M 914.80M 1.29%
2026-04-29 Fidelity Concord Street Trust-Fidelity 500 Index Fund 19.00M 906.33M 1.28%
2026-04-29 SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust 17.73M 845.54M 1.19%
Split
Split Date
2 : 1 2003-11-06
2 : 1 1998-12-01